272 related articles for article (PubMed ID: 38430889)
21. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
22. Gut microbiome in modulating immune checkpoint inhibitors.
Li X; Zhang S; Guo G; Han J; Yu J
EBioMedicine; 2022 Aug; 82():104163. PubMed ID: 35841869
[TBL] [Abstract][Full Text] [Related]
23. Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers.
McQuade JL; Ologun GO; Arora R; Wargo JA
Curr Oncol Rep; 2020 Jun; 22(7):74. PubMed ID: 32577835
[TBL] [Abstract][Full Text] [Related]
24. Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects.
Boesch M; Horvath L; Baty F; Pircher A; Wolf D; Spahn S; Straussman R; Tilg H; Brutsche MH
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36343977
[TBL] [Abstract][Full Text] [Related]
25. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
Renga G; Nunzi E; Pariano M; Puccetti M; Bellet MM; Pieraccini G; D'Onofrio F; Santarelli I; Stincardini C; Aversa F; Riuzzi F; Antognelli C; Gargaro M; Bereshchenko O; Ricci M; Giovagnoli S; Romani L; Costantini C
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236743
[TBL] [Abstract][Full Text] [Related]
26. The triple interactions between gut microbiota, mycobiota and host immunity.
Yang J; Yang H; Li Y
Crit Rev Food Sci Nutr; 2023 Nov; 63(33):11604-11624. PubMed ID: 35776086
[TBL] [Abstract][Full Text] [Related]
27. Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy.
He Y; Huang J; Li Q; Xia W; Zhang C; Liu Z; Xiao J; Yi Z; Deng H; Xiao Z; Hu J; Li H; Zu X; Quan C; Chen J
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358736
[TBL] [Abstract][Full Text] [Related]
28. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
[No Abstract] [Full Text] [Related]
29. Adjunctive Probiotic
Gao G; Ma T; Zhang T; Jin H; Li Y; Kwok LY; Zhang H; Sun Z
Front Immunol; 2021; 12():772532. PubMed ID: 34970262
[TBL] [Abstract][Full Text] [Related]
30. Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy.
Davar D; Zarour HM
Clin Cancer Res; 2022 Oct; 28(20):4370-4384. PubMed ID: 35748749
[TBL] [Abstract][Full Text] [Related]
31. Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy.
Gao X; Jiang J
Front Immunol; 2024; 15():1359029. PubMed ID: 38617841
[TBL] [Abstract][Full Text] [Related]
32. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer.
Kim E; Ahn H; Park H
Mamm Genome; 2021 Aug; 32(4):223-231. PubMed ID: 33783613
[TBL] [Abstract][Full Text] [Related]
33. Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend?
Zhao H; Wang D; Zhang Z; Xian J; Bai X
Molecules; 2022 Jul; 27(15):. PubMed ID: 35956752
[TBL] [Abstract][Full Text] [Related]
34. Gut microbiota modulation: a tool for the management of colorectal cancer.
Wang Y; Li H
J Transl Med; 2022 Apr; 20(1):178. PubMed ID: 35449107
[TBL] [Abstract][Full Text] [Related]
35. Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: An emerging trend in cancer patient care.
Ciernikova S; Sevcikova A; Drgona L; Mego M
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188990. PubMed ID: 37742728
[TBL] [Abstract][Full Text] [Related]
36. A Review of Gut Microbiota-Derived Metabolites in Tumor Progression and Cancer Therapy.
Yang Q; Wang B; Zheng Q; Li H; Meng X; Zhou F; Zhang L
Adv Sci (Weinh); 2023 May; 10(15):e2207366. PubMed ID: 36951547
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment.
Xu H; Cao C; Ren Y; Weng S; Liu L; Guo C; Wang L; Han X; Ren J; Liu Z
Front Immunol; 2022; 13():949490. PubMed ID: 36177041
[TBL] [Abstract][Full Text] [Related]
38. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
[TBL] [Abstract][Full Text] [Related]
39. The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors.
Joachim L; Göttert S; Sax A; Steiger K; Neuhaus K; Heinrich P; Fan K; Orberg ET; Kleigrewe K; Ruland J; Bassermann F; Herr W; Posch C; Heidegger S; Poeck H
EBioMedicine; 2023 Nov; 97():104834. PubMed ID: 37865045
[TBL] [Abstract][Full Text] [Related]
40. Microbial Influences on Immune Checkpoint Inhibitor Response in Melanoma: The Interplay between Skin and Gut Microbiota.
Bouferraa Y; Fares C; Bou Zerdan M; Boyce Kennedy L
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
